Early systemic inflammation induces neurodevelopmental disorders: results from ARTEMIS, a French multicenter study of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders and meta-analysis.
Pierre EllulIsabelle MelkiStephanie AntounLaura LavialleEric AcquavivaFlorence A AeschlimannBrigitte Bader-MeunierAlexandre BelotGlory DinguluCecile DumaineAlbert FayeMarie-Louise FrémondUlrich MeinzerHugo PeyrePierre QuartierMichelle RosenzwajgIsabelle SaviozCaroline VinitNicolas TchitchekDavid KlatzmannRichard DelormePublished in: Molecular psychiatry (2023)
Prenatal immune-mediated events are known risk factors for neurodevelopmental disorders in the offspring (NDD). Although the brain continues to develop for years after birth and many postnatal factors alter the regular trajectory of neurodevelopment, little is known about the impact of postnatal immune factors. To fill this gap we set up ARTEMIS, a cohort of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders (jRSAID), and assessed their neurodevelopment. We then complemented our results with a systematic review and meta-analysis. In ARTEMIS, we used unsupervised and supervised analysis to determine the influence of jRSAID age at onset (AO) and delay in introduction of disease-modifying therapy (DMT) on NDD (NCT04814862). For the meta-analysis, we searched MEDLINE, EMBASE, PsycINFO, Cochrane, and Web of Science up to April 2022 without any restrictions on language, or article type for studies investigating the co-occurence of jRSAID and NDD (PROSPERO- CRD42020150346). 195 patients were included in ARTEMIS. Classification tree isolated 3 groups of patients (i) A low-risk group (AO > 130 months (m)) with 5% of NDD (ii) A medium-risk group (AO < 130 m and DMT < 2 m) with 20% of NDD (iii) and a high-risk-group (AO < 130 m and DMT > 2 m) with almost half of NDD. For the meta-analysis, 18 studies encompassing a total of (i) 46,267 children with jRSAID; 213,930 children with NDD, and 6,213,778 children as controls were included. We found a positive association between jRSAID and NDD with an OR = 1.44 [95% CI 1.31; 1.57] p < 0.0001, [I 2 = 66%, Tau 2 = 0.0067, p < 0.01]. Several sensitivity analyses were performed without changing the results. Metaregression confirmed the importance of AO (p = 0.005). Our study supports the association between jRSAID and NDD. AO and DMT have pivotal roles in the risk of developing NDD. We plead for systematic screening of NDD in jRSAID to prevent the functional impact of NDD.
Keyphrases
- systematic review
- end stage renal disease
- machine learning
- young adults
- newly diagnosed
- chronic kidney disease
- ejection fraction
- case control
- peritoneal dialysis
- multiple sclerosis
- randomized controlled trial
- oxidative stress
- preterm infants
- pregnant women
- public health
- deep learning
- stem cells
- metabolic syndrome
- meta analyses
- type diabetes
- autism spectrum disorder
- brain injury
- patient reported
- patient reported outcomes
- mesenchymal stem cells
- functional connectivity
- resting state
- gestational age